Response to: Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period

Sam Nightingale¹, Anna J Dreyer¹, Magnus Gisslén^{2

3}, Alan Winston^{4

5}, John A Joska¹

Affiliations

¹ HIV Mental Health Research Unit, Department of Psychiatry and Mental Health, Neuroscience Institute, Cape Town, South Africa.
² Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg.
³ Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
⁴ Department of Infectious Disease, Imperial College London.
⁵ HIV Clinical Trials, Winston Churchill Wing, St Mary's Hospital, London, UK.

Comment

Sam Nightingale et al. AIDS. 2021.

. 2021 Jun 1;35(7):1152-1153.

doi: 10.1097/QAD.0000000000002848.

Sam Nightingale¹, Anna J Dreyer¹, Magnus Gisslén^{2

3}, Alan Winston^{4

5}, John A Joska¹

¹ HIV Mental Health Research Unit, Department of Psychiatry and Mental Health, Neuroscience Institute, Cape Town, South Africa.
² Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg.
³ Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
⁴ Department of Infectious Disease, Imperial College London.
⁵ HIV Clinical Trials, Winston Churchill Wing, St Mary's Hospital, London, UK.

No abstract available

Comment on

Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period.
Rourke SB, Bekele T, Rachlis A, Kovacs C, Brunetta J, Gill MJ, Carvalhal A, Cysique LA, Marcotte T, Power C. Rourke SB, et al. AIDS. 2021 Jan 1;35(1):63-72. doi: 10.1097/QAD.0000000000002709. AIDS. 2021. PMID: 33048883

1. Rourke SB, Bekele T, Rachlis A, Kovacs C, Brunetta J, Gill MJ, et al. Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period . AIDS 2021; 35:63–72.
1. Ferretti F, Mora-Peris B, Underwood J, Waldman A, Everitt A, Winston A. Cognitive impairment in a clinical setting . J Acquir Immune Defic Syndr 2018; 77:e10–e13.
1. Revicki DA, Chan K, Gevirtz F. Discriminant validity of the medical outcomes study cognitive function scale in HIV disease patients . Qual Life Res 1998; 7:551–559.
1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders . Neurology 2007; 69:1789–1799.
1. Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study . Neurology 2016; 86:334–340.